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Purpose: Endobronchial metastasis is defined as documented extrathoracic malig-
nancies metastatic to the endobronchus within a bronchoscopically visible range. 
Although the clinical and radiologic findings of endobronchial metastasis are simi-
lar to primary lung cancer, treatment and prognosis may be different. We hereby 
investigated the clinical, radiologic and bronchoscopic aspects of endobronchial 
metastases (EBM) in Korean patients. Materials and Methods: A total of 43 pa-
tients with EBM who underwent bronchoscopic biopsies from June 1991 to De-
cember 2009 at Severance Hospital, Yonsei University College of Medicine in 
Seoul, Korea, were analyzed retrospectively. We evaluated clinical, radiologic and 
bronchoscopic characteristics of EBM. Results: The patients consisted of 27 
males and 16 females and their ages ranged from 18 to 77 years. The common pri-
mary cancers related to EBM were rectal (16.3%), colon (11.6%), breast (9.3%) 
and uterine (9.3%) cancers. The mean interval from diagnosis of primary cancer to 
EBM was 36 months, and the mean survival duration from diagnosis of EBM was 
16.1 months in 33 deceased patients. Conclusion: EBM develop in various types 
of malignancies at various times with unremarkable manifestations. Therefore, 
physicians should consider the possibility of EBM, especially if a patient has a his-
tory of any malignancy, regardless of respiratory symptoms. Respiratory symp-
toms related with EBM can be treated by various safe procedures.
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INTRODUCTION
Endobronchial lesions have many different histological causes, the most frequent 
being bronchogenic small cell carcinoma, well-differentiated neuroendocrine car-
cinoma, bronchogenic squamous cell carcinoma and non-small cell carcinoma.1 
Only 1.1% of endobronchial tumors are metastatic.2 However, the incidence of en-
dobronchial metastases (EBM) differs according to the status of disease, patient 
group, and study program used.3-5 According to the study by Oshikawa, et al.,4 the 
incidence of EBM was reported as 15 cases (23%) out of 65 patients with meta-
static pulmonary disease. In another study by Braman and Whitcomb,3 EBM were 
readily visible bronchoscopically in the main bronchus and lobar bronchus, and 
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We retrospectively reviewed the medical records of all 43 
patients and collected data on baseline characteristics, his-
topathological results, the interval of time from the primary 
tumor diagnosis to EBM diagnosis, clinical symptoms, ra-
diologic findings, including chest X-ray and computed to-
mography, developmental modes, treatment modalities, and 
survival time. 
A flexible bronchoscopy was performed by a pulmonolo-
gist under sedation for each patient. Histopathologic diag-
nosis was confirmed in all cases by direct biopsy with bron-
choscopy. EBM were defined as bronchoscopically visible 
involvement of the subsegmental or more proximal central 
bronchus with histologically verified extrathoracic primary 
malignancy. Primary lung cancer, esophageal cancer and 
lymphoma were excluded in this study because these can-
cers can invade the bronchus directly without metastasis.
The developmental mode of EBM was classified into 
four groups, according to Kiryu, et al.,18 using chest images, 
bronchoscopic findings, and histology, as follows: type I, 
direct metastasis to the bronchus; type II, endobronchial in-
vasion of parenchymal mass; type III, endobronchial inva-
sion of mediastinal or hilar lymphadenopathy; and type IV, 
extension of peripheral tumor along the proximal bronchus.
This study protocol was approved by the Institutional Re-
view Board of Severance Hospital.
 
RESULTS
 
Patient characteristics and presenting symptoms
Patient characteristics and presenting symptoms are sum-
marized in Table 1. The 43 patients consisted of 27 males 
and 16 females. Their ages ranged from 18 to 77, with a 
mean age of 55.1 years. The most common presenting symp-
toms were cough in 22 (51.2%) patients and dyspnea in 12 
(27.9%) patients. Twelve patients (27.9%) with EBM were 
asymptomatic. Nine patients were detected by routine fol-
low-up examination, two patients while evaluating other 
symptoms and one patient by medical check-up. 
Clinical findings of patients with endobronchial 
metastases
Clinical findings of patients with endobronchial metastases 
are shown in Table 2. Common primary cancers related 
with EMB were rectal (7 patients, 16.3%), colon (5 pa-
tients, 11.6%), breast (4 patients, 9.3%) and uterine (4 pa-
tients, 9.3%) cancers. The others included stomach, thyroid, 
the prevalence of EBM was 2%.
From a histopathologic standpoint, EBM are observed in 
various types of malignancies including colorectal, breast, 
kidney, stomach, ovarian, thyroid, uterine, testicular, naso-
pharynx, prostate, adrenal carcinomas, sarcomas, histocyto-
ma and plasmacytomas.6-10 In addition, many other benign 
etiologic tumors have been reported, such as fungal disease, 
inflammatory pseudopolyp, lipoma and broncholith.11 The 
most common EBM are colorectal, breast and kidney carci-
nomas.12,13 Although there are many underlying causes, 
most have similar clinical presentations such as cough, dys-
pnea and sputum. 
Metastases from non-pulmonary malignancies to the 
lungs are very common, but EBM from extrathoracic ma-
lignancy are rare. Moreover, it is difficult to distinguish 
bronchogenic carcinoma from metastasis of extrathoracic 
malignancies. However, the treatment modality of EBM is 
determined by the histologic features of the primary tumor, 
biologic behavior, anatomic location, evidence of other 
metastatic sites, present symptoms, patient performance 
status and life expectancy. Therefore, the accurate diagnosis 
of EMB is very important for decisions regarding treatment 
modality.14 Only a small number of cases have been report-
ed in Korea.15-17 The objective of this study was to investi-
gate the clinical, radiologic and bronchoscopic aspects of 
EMB in Korean patients.
MATERIALS AND METHODS
We retrospectively reviewed all fibrobronchoscopic reports 
from June 1991 to December 2009 at Severance Hospital, 
Yonsei University College of Medicine, in Seoul, Korea 
and identified 43 patients who were diagnosed with EMB. 
Table 1. Patient Characteristics
Variables Number n=43
Male/Female, No     27/16 (62.8/37.2)
Mean age (range), yrs 55.1 (18-77)
Symptom, No.
    Cough  22 (51.2)
    Dyspnea  12 (27.9)
    Sputum    7 (16.3)
    Hemoptysis    6 (14.0)
    Chest pain    5 (11.6)
    Other symptom
        Fever  2 (4.7)
        Weight loss  1 (2.3)
    No symptom  12 (27.9)
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deceased patients. 
Location of endobronchial metastases
There were 50 bronchoscopically visible endobronchial le-
sions, and their locations are listed in Table 3. EMB were 
observed at the left bronchus in 21 patients (48.8%) and at 
the right bronchus in 28 patients (65.1%). One colon cancer 
patient had three bronchoscopically visible endobronchial 
hepatoma, melanoma, nasopharynx, osteosarcoma, pros-
tate, kidney, urothelial, fibrosarcoma originating from left 
calf, salivary gland, parotid gland, cervix, and malignant fi-
brous histocytoma originating from the left thigh. The pri-
mary tumor site could not be detected in one of the patients 
with melanoma. Thirty-six patients (83.7%) had a previous 
history of extrathoracic malignancy. In seven patients, 
EBM were diagnosed at the same time as diagnosis of the 
following primary tumors: melanoma (2), prostate (2), pa-
rotid gland (1), salivary gland (1) and stomach (1) cancers. 
The interval time from diagnosis of the primary tumor to 
the diagnosis of EBM was between 0 to 160 months, with 
a median period of 36 months. The time interval between 
detection of the primary tumors and EMB was relatively 
long for thyroid (156 months), breast (111 months) and 
rectal (96 months) cancers. The treatment modalities were 
surgery in nine, chemotherapy in 17, radiotherapy in 10, 
chemotherapy combined with radiotherapy in one, and 
supportive care in 11 patients. Two patients received che-
motherapy and surgery. The mean survival time from diag-
nosis of endobronchial metastasis was 16.1 months in 33 
Table 2. Clinical Findings in 43 Patients with Endobronchial Metastases Diagnosed by Bronchoscopy with Biopsy
Primary site
No. of 
patients 
Time*
(median), months
Treatment Survival†, 
(median), monthsSurgery CTx RTx Others SC
Rectum 7 17-156 (96.0) 3 3 1  1‡ -    3-24 (9.5)
Colon 5     1-67 (24.0) 2 1 - - 2      3-59 (14.0)
Breast 4   34-132 (111.0) - 1 1 - 2    13-57 (16.5)
Uterine 4   17-40 (31.0) - - 2 - 2    5-10 (8.3)
Stomach 3     0-60 (41.0) - 3 1 - - 4-18 (8)
Thyroid 3   18-160 (156.0) - - 2  1§ - 49
Hepatoma 2   69-95 (82.0) 1 2 1 - - 14-22 (18)
Melanoma 2   0 - 1 - - 1   2-34 (18)
Nasopharynx 2     3-38 (20.5) - 1 1 - 1      3-6 (4.5)
Osteosarcoma 2   22-26 (24.0) 1 1 - - 1 31
Prostate 2   0 - 2 - - - 5
Kidney 1 65 - 1 - - - -||
Urothelial 1 19 - - 1 - - 4
Fibrosarcoma 1 84 1 - - - - 14
Salivary 1   0 - - - - 1 13
Parotid 1   0 - 1 - - - 33
Cervix 1 23 - - - - 1 0
Histocytoma 1 28 1 - - - - 15
Total 43    2187 (36.0) 9 17 10 2 11      0-59 (16.1)
RTx, radiotherapy; CTx, chemotherapy; SC, supportive care.
*Interval between diagnosis of primary tumor and endobronchial metastasis.
†Survival time from diagnosis of endobronchial metastasis. 
‡Photodynamic therapy.
§Radioactive iodine therapy.
||Survival is unknown.
Table 3. Location of Endobronchial Metastases Diagnosed 
by Bronchoscopy with Biopsy
Location
No. of patients
Bronchus
Left Right
Trachea 1 - -
Multiple sites 6 - -
Main bronchus - 9 6
Upper lobe bronchus - 4 8
Middle lobe bronchus - - 6
Lingular - 1 -
Lower lobe bronchus - 7 8
Total 7 21 28
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lesions. One melanoma, two prostate cancer, one rectal can-
cer, and one stomach cancer patient had two visible endo-
bronchial lesions.
Radiologic findings of endobronchial metastases
The radiologic findings of 50 EMB are summarized in Ta-
ble 4. Six patients had multiple lesions. Hilar mass (15 pa-
tients, 34.9%) was the most frequent finding on chest radi-
ography, followed by visible tumors (11 patients, 25.6%), 
atelectasis (10 patients, 23.3%) and multiple nodules (10 
Table 4. Radiologic Findings in 43 Patients with Endobron-
chial Metastasis Diagnosed by Bronchoscopy with Biopsy
Radiologic findings No. of patients (%)
Hilar mass  15 (34.9) 
Visible tumors 11 (25.6)
Atelectasis 10 (23.3)
Multiple nodules  10 (23.3) 
Normal 4 (9.3)
Pleural fluid 3 (7.0)
Mediastinal mass 2 (4.7)
Table 5. Treatment and Outcome after EBM Diagnosis
Case No. Age/Sex
Primary 
tumor site
Initial symptom
Interval* 
(months)
Treatment after 
EBM diagnosis
Survival 
(months)
Outcome
1 F/63 Thyroid Hemoptysis 160 RTx 49 Dead
2 F/77 Thyroid Asymptomatic 156 RTx - Unknown
3 M/69 Thyroid Cough   18 131-Iodine - Alive†
4 F/53 Breast Cough 108 RTx 17 Dead
5 F/43 Breast Asymptomatic   34 SC 13 Dead
6 F/55 Breast Cough 114 SC 57 Dead
7 F/57 Breast Asymptomatic 132 CTx 16 Dead
8 M/52 Liver Dyspnea   95 CTx, RTx, Surgery 22 Dead
9 M/62 Rectum Cough 156 Phototherapy - Alive‡
RTx, radiotherapy; CTx, chemotherapy; SC, supportive care; EBM, endobronchial metastases.
*Interval between diagnosis of primary tumor and endobronchial metastasis. 
†The patient was still alive at 2 months.
‡The patient was still alive at 6 months.
Table 6. Classification of Developmental Modes of Endobronchial Metastases and Metastases to Other Organs
Primary site
No. of
patients 
Developmental mode of EBM (type) Metastases to other organ
I II III IV
Paren-
chyme
Pleura Brain Liver Bone Other
Rectum 7 4 3 - - 2 - - - - -
Colon 5 2 - - 3 3 - 1 1 1 -
Breast 4 - 2 1 1 2 - - - 2 -
Uterus 4 1 1 1 1 1 1 - 1 3 -
Stomach 3 - - 3 - - - - - 2 Ovary
Thyroid 3 2 1 - - 2 1 - - - -
Hepatoma 2 1 1 - - 1 - - - 1 -
Melanoma 2 1 - - 1 - - - 1 - -
Nasopharynx 2 1 - - 1 1 - - 1 - -
Osteosarcoma 2 1 1 - - - - - - - Kidney
Prostate 2 - 1 - 1 1 - - - - -
Kidney 1 - - 1 - 1 - - - - -
Urothelial 1 - 1 - - 1 - - - - -
Fibrosarcoma 1 1 - - - 1 - - - - -
Salivary 1 1 - - - - - - - - -
Parotid 1 1 - - - 1 - - - - Elbow
Cervix 1 - 1 - - 1 - - - - -
Histocytoma 1 - - - 1 - 1 - - - -
Total 43 16 12 6 9 18 3 1 4 9 3
EBM, endobronchial metastases.
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important to select treatment modalities for individual pa-
tients. However, EBM are probably underestimated, be-
cause bronchoscopy is not used routinely in patients with 
malignancy history. Staining bronchoscopy, macroscopic 
bronchoscopy or auto-fluorescence bronchoscopy can be 
used to detect less invasive endobronchial tumors early, thus 
allowing earlier treatment and a better prognosis. Moreover, 
electronic noses are also available in early detection of 
bronchogenic carcinoma.19 In many studies, EBM are clini-
cally, radiologically and bronchoscopically indistinguish-
able from bronchogenic carcinoma in most cases. They 
should be confirmed by histological analysis and the patho-
logic comparison of EBM and the primary site is important. 
Rosenblatt, et al.20 showed that the distinct features of meta-
static bronchial lesions in the early stage included an intact 
epithelium covering the tumor mass with subepithelial lym-
phatics. Clear cell renal cancer is easily diagnosed by im-
munohistochemistry using markers such as CK7, CK20, 
thyroid transcription factor-1 and apoprotein-A1.21-23 These 
molecular biologic tools are very useful to distinguish ex-
trathoracic lung metastasis from primary lung cancer.
The interval between diagnosis of primary cancer and de-
tection of EBM is reported to be about 50 months and our 
study revealed an average interval of 36 months.13 This peri-
od was long compared to the average intervals for metasta-
sis to other organs in these cancers.24 This might mean that 
EBM frequently occur in “well-controlled” primary cancer. 
However, there is no obvious explanation for this phenome-
non. As our study demonstrated, EBM may not indicate a 
poor prognosis and should not be thought a bad prognostic 
factor in choosing treatment modalities. Akoglu, et al. showed 
that mean survival time was longer in patients with chemo-
therapy or radiotherapy than in patients with supportive 
care.14 After diagnosis of EBM, the median survival dura-
tion was 16.1 months in our study, similar to the 15.5 months 
found by Kiryu, et al.18 Larger studies may be required to 
evaluate molecular markers for genes that would explain 
the characteristics of these time intervals. 
EBM are known to manifest late in the course of cancer 
progression. However, there are cases of lesions being diag-
nosed at the same time as primary tumors.25 In our study, 
EBM and primary cancer were diagnosed simultaneously 
in seven patients with melanoma, prostate, parotid, salivary 
and stomach cancers. The most common metastatic sites of 
melanoma are lung and liver, and EBM were found at the 
same time as diagnosis of all melanomas in this study.26 
Moreover, prostate cancer is commonly diagnosed simulta-
patients, 23.3%). Four patients (9.3%) showed normal ra-
diologic findings and three of them had rectal cancer.
Treatment and outcome after EBM diagnosis in long-
term survivors
Mean survival time after EBM diagnosis in long-term sur-
vivors who were treated was 17.4 months, whereas that of 
patients given supportive care was 12.4 months. Treatment 
and outcome after EBM diagnosis in some long-term sur-
viors are shown in Table 5. EBM related with thyroid, breast 
or rectal cancer appear less aggressive than in other malig-
nancies. One of the thyroid cancer patients who received a 
total thyroidectomy due to recurrence six years after initial 
partial thyroidectomy showed re-recurrence as EBM after 
an additional seven-year period. One patient with hepato-
cellular carcinoma received chemotherapy, radiotherapy 
and surgery, and he lived for more than ten years after these 
multidisciplinary treatments. One patient with rectal cancer 
received photodynamic therapy and one patient with thy-
roid cancer received radioactive iodine therapy.
Classification of developmental modes of endobronchial 
metastases and metastases to other organs
Classifications of the developmental modes of endobron-
chial metastases and the involvement of other organs are 
shown in Table 6. Patients were divided into four groups ac-
cording to the classification of developmental modes: type I, 
16 patients (37.2%); type II, 12 patients (27.9%); type III, 6 
patients (14.0%); and type IV, 9 patients (20.9%). In 13 pa-
tients, extrathoracic metastases were present at the same 
time as EBM diagnosis. The most common extrathoracic 
metastatic site was bone. 
DISCUSSION
In this study, we analyzed the clinical, radiologic and bron-
choscopic aspects of EBM in Korean patients. EBM were 
most frequently detected in colorectal, breast and uterine 
cancers and the main bronchus was the most common site 
of the primary tumor. Cough and a hilar mass on radiogra-
phy were the most frequent clinical manifestations.
EBM from an extrathoracic primary tumor are very 
rare.13 When an endobronchial mass is detected, it is impor-
tant to distinguish primary lung cancer from lung metasta-
sis of extrathoracic primary tumors. Primary lung cancer 
and EBM have different prognoses, so diagnosis is very 
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astatic spread is needed.
The present study had several limitations. First, the types 
of primary tumors with EBM varied in this study, so overall 
prognosis would not represent the characteristics of each 
malignancy. Second, there were many improvements in the 
diagnosis and treatment of malignancies during this study 
period between 1991 and 2009. These improvements would 
influence the disease progression even in the same type of 
malignancy.
In conclusion, this study suggests that EBM develop in 
various types of malignancies at various times. However, 
the incidence of EBM has been underestimated because of 
its unremarkable manifestations. Some patients with EBM 
show no clinical symptoms or normal image findings. How-
ever, EBM should be distinguished from primary lung can-
cer through histological confirmation, and bronchoscopy in 
these asymptomatic or radiologically free patients with ma-
lignancy is useful. Moreover, respiratory symptoms of EBM 
may be treated by various safe procedures, and in some cas-
es, intrabronchial therapy may prolong patient survival.7 
Therefore, physicians should consider the possibility of 
EBM when they encounter patients with colorectal or breast 
cancer, especially when respiratory symptoms are present. 
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